Progesterone receptor antagonist therapy has therapeutic potential even in cancer restricted to males as evidenced from murine testicular and prostate cancer studies

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4921-4924

  Check, Jerome H ^a,b,c   Ebony, Dix ^a,b,c   Wilson, Carrie ^c   Check, Diane ^c  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Mifepristone; Murine prostate cancer; Progesterone receptor antagonists; Testicular cancer

Indexed keywords

MIFEPRISTONE; PROGESTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CANCER CLASSIFICATION; CANCER SURVIVAL; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TESTIS CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HORMONE ANTAGONISTS; MALE; MICE; MICE, INBRED C57BL; MIFEPRISTONE; PREGNANCY; PROGESTERONE; PROSTATIC NEOPLASMS; RECEPTORS, PROGESTERONE; TESTICULAR NEOPLASMS;

EID: 78751479821     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Check JH, Nazari P, Goldberg J, Yuen W and Angotti D: A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypoth 57: 337-343, 2001.
2. Check JH, Dix E and Sansoucie L: Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein. Med Hypoth 72: 87-90, 2009.
3. Srivastava MD, Thomas A, Srivastava BI and Check JH: Expression and modulation of progesterone-induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma 48: 1610-1617, 2007.
4. Check JH, Sansoucie L, Chern J, Amadi N and Katz Y: Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia. Anticancer Res 29(8): 2977-2980,2009.
5. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH and Lee EY: Prevention of Brea 1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314: 1467-1470, 2006.
6. Check JH, SanSoucie L, Chern J and Dix E: Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Research 30: 119-122, 2010.
7. Acevedo HF, Tong JY and Hartsock RJ: Human chorionic gonadotropin-beta subunit gene expressino in cultured human fetal and cancer cells of different types and origins. Cancer 76: 1467-1475, 1995.
8. Acevedo HF, Longinotti SM and Marquardt M: Expression of hCG, its subunits and fragments by human cultured cancer cells of the nervous system. Cancer Detect Prevent 19: 37, 1995.
9. Acevedo HF, Campbell-Acevedo GA, Buffo MK and Krichevsky A: In vivo expression of membrane-associated human chorionic gonadotropin by cells isolated from cancerous human tissues. Proc Am Assoc Cancer Res 34: 27, 1994.
10. Szekeres-Bartho J, Csernus V and Hadnagy J: The blocking effect of progesterone on lymphocyte responsiveness is receptormediated. Biol Immunol Reprod 15: 36, 1989.
11. Szekeres-Bartho J, Faust Zs and Varga P: The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Am J Reprod Immunol 34: 342, 1995.
12. Check JH, Szekeres Bartho J and O'Shaughnessy A: Progesterone-induced blocking factor seen in pregnancy lymphocytes soon after implantation. Am J Reprod Immunol 35: 277-280, 1996.
13. Check JH, Arwitz M, Gross J, Peymer M and Szekeres Bartho J: Lymphocyte immunotherapy (LI) increases serum levels of progesterone-induced blocking factor. Am J Reprod Immunol 37: 17-20, 1997.
14. Check JH, Arwitz M, Gross J, Szekeres-Bartho J and Wu CH: Evidence that the expression of progesterone-induced blocking factor by maternal T-lymphocytes is positively correlated with conception. Am J Reprod Immunol 38(1): 6-8, 1997.
15. Check JH, Ostrzenski A and Klimek R: Expression of an immunomodulatory protein known as progesterone-induced blocking factor (PIBF) does not correlate with first trimester spontaneous abortions in progesterone-supplemented women. Am J Reprod Immunol 37: 330-334, 1997.
16. Check JH, Szekeres-Bartho J, Nazari P, Katz Y and Check ML: A corpus luteum is not a prerequisite for the expression of progesterone-induced blocking factor by T-lymphocytes a week after implantation. J Assist Reprod Genet 18: 603-607, 2001.
17. Check JH, Dix E, SanSoucie L and Check D: Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report. Anticancer Res 29(5): 1611-1613, 2009.
18. Check JH, Dix E, Cohen R, Check D and Wilson C: Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res 30(2): 623-628, 2010.